Evidence map›Paper›PMID 38799439›Full record

ArticleFrontiers in immunology2024

A TLR4 ligand-based adjuvant for promoting the immunogenicity of typhoid subunit vaccines.

Kishore R Alugupalli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Kishore R AlugupalliDepartment of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA, United States.

Funding

A System to Study Salmonella Typhi Infection and ImmunityR21AI159798 · NIAID · THOMAS JEFFERSON UNIVERSITY · PI ALUGUPALLI, KISHORE R · 2021 to 2022
$429k
NIAID NIH HHS R21 AI159798
6 · The paper itself

Abstract

None of the typhoid Vi Polysaccharide (ViPS) subunit vaccines incorporate adjuvants, and the immunogenicity of ViPS vaccines (e.g. Typbar TCV

Indexed as

Adjuvants, ImmunologicAntibodies, BacterialLipid AToll-Like Receptor 4Typhoid FeverTyphoid-Paratyphoid VaccinesVaccines, SubunitAdjuvants, VaccineAnimalsFemaleImmunogenicity, VaccineImmunoglobulin GLigandsMiceMice, Inbred BALB CPolysaccharides, BacterialAdjuvants, ImmunologicAdjuvants, VaccineAntibodies, BacterialImmunoglobulin GLigandsLipid Amonophosphoryl lipid APolysaccharides, BacterialTlr4 protein, mouseToll-Like Receptor 4Typhoid-Paratyphoid VaccinesVaccines, SubunitVi polysaccharide vaccine, typhoidadjuvantSalmonellatoll-like receptortyphoidvaccineVi polysaccharide

Identifiers

PMID38799439
PMCPMC11116679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.